Online ISSN: 2515-8260

Keywords : Pre-Eclampsia


Clinical Study of Neonates Born to Mothers with Hypertensive Disorders of Pregnancy (HDP)

Gajula Ravi, Janardhan Reddy Pulluru, Suraboina Satishkumar

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 10414-10423

Background:Globally, hypertensive disorders of pregnancy (HDP) are one of the major
causes of perinatal and maternal morbidity and mortality. These disorders are
characterized by increase in blood pressure (BP) which may be present before or
appear for the first time during pregnancy after 20 weeks with or without proteinuria
or evidence of multiorgan involvement and have been classified into preeclampsia (PE)
and eclampsia syndrome, chronic hypertension (CH), PE superimposed on CH, and
gestational hypertension. The HDP may complicate 5%–10% of all the pregnancies
with the prevalence of 6.9%–7.9% in India. Studies have shown that HDP accounts for
around 16% of 2.6 million stillbirths and 15% of perinatal deaths globally. Higher rates
of adverse perinatal outcome such as preterm delivery, low birth weight, birth asphyxia,
stillbirth, and early death have been reported worldwide in women having
HDP.Prematurity and preterm birth are documented as the most common cause of
perinatal death in Indian women with HDP. The present study was conducted with the
aim to know the type of hypertension affecting the pregnant women and perinatal
outcome.Aims and objectives:To determine the outcome of neonates born to mothers
with Hypertensive Disorders of pregnancy in comparison with neonatal outcome in
babies born to normotensive mothers.
Materials and Methods: A comparative case control study will be performed on
Neonates fitting into inclusion criteria from JAN 2019 to Jun 2020 and a
prestructuralperforma will be used to obtain detailed History taking, Clinical
examination .The comparison will be done between two groups. The study group, which
will include neonates born to mothers with either gestational hypertension,
preeclampsia or eclampsia. The control group, which will include all babies born to
normotensive mothers, matched forgestation with the study group during the study
period.
Results: The results showed that the primary and the secondary outcomes in the study
group was significantly poorer compared to control group. There was significantly high
rate of death among the neonates born in the study group (p< 0.05).Also there was
higher rate of meconium stained amniotic fluid (16%), more requirement of surfactant
(14%) and more requirement of NICU admission (31%) among the study group. There
was also higher rate of IUGR (20%) as well as higher rates of Low birth weights among
study group.

Association between second trimester maternal serum alphafetoprotein in 14-22 weeks and adverse pregnancy outcome

Heena Mir, Saima Sadiq,Sabha Malik

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 225-230

Background:Many screening tests are available for predicting adverse pregnancy outcome
and these range from non- invasive to invasive and serum alpha-fetoprotein level
estimation is one of them. The present study was conducted to assess association between
second trimester maternal serum alpha-fetoprotein in 14-22 weeks and adverse pregnancy
outcome.
Materials & Methods: 250 patients of gestational age between 14-22 weeks were included.
Maternal serum alpha-fetoprotein was measured in human serum by microplateimmunoenzymometric
assay by EIA-AFP kit. Maternal serum alpha-feto protein level was
expressed in IU/ml.
Results: 23 (9.2%) participants out of 250 developed preterm labor. 21 out of 23 had raised
value of maternal serum alpha-fetoprotein. 20 (8%) patients out of 250 patients developed
oligohydramnios. 13 out of 20 had raised value of maternal serum alpha-fetoprotein. 14
(5.6%) patients out of 250 developed pre-eclampsia, 11 out of 14 had raised values of
maternal serum alpha-fetoprotein. 7 (2.8%) patients out of 250 developed premature
rupture of membrane (PROM). 4 out of 7 had raised values of maternal serum alphafetoprotein.
Conclusion: There is an increased risk of pre-eclampsia, preterm delivery,
oligohydramnios and premature rupture of membrane with elevated maternal serum
alpha-fetoprotein levels